• 1
    Gupta A K, Brown M D, Ellis C N et al. Cyclosporine in dermatology. J Am Acad Dermatol 1989: 21: 12451256.
  • 2
    Reitamo S, Rustin M, Ruzicka T et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002: 109: 547555.DOI: 10.1067/mai.2002.121832
  • 3
    Reitamo S, Van Leent E J M, Ho V et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002: 109: 539546.DOI: 10.1067/mai.2002.121831
  • 4
    Rico M, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacological effects. Allergy Asthma Proc 2002: 23: 191197.
  • 5
    Griffith C E, Powles A V, Baker B S et al. Topical cyclosporine and psoriasis (letter). Lancet 1987: i: 806.DOI: 10.1016/S0140-6736(87)92829-7
  • 6
    Jegasothy B V, Ackerman C D, Todo S, Fung J J, Abu-Elmagd K, Starzl T E. Tacrolimus (FK 506) – a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992: 128: 781785.DOI: 10.1001/archderm.128.6.781
  • 7
    European FK 506 Multicenter Psoriasis Study Group. Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996: 132: 419423.DOI: 10.1001/archderm.132.4.419
  • 8
    Stuetz A, Grassberger M, Meingassner J G. Entstehungsgeschichte und präklinisches Profil von Pimecrolimus. Hautarzt 2003: 54: 405412.
  • 9
    Wellington K, Jarvis B. Topical pimecrolimus. A review of its clinical potential in the management of atopic dermatitis. Drugs 2002: 62: 817840.
  • 10
    Eichenfield L F, Beck L. Elidel (pimecrolimus) cream 1%: a non-steroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol. 2003: 111: 11541168.
  • 11
    Graham-Brown R A C, Grassberger M. Pimecrolimus: a review of preclinical and clinical data. Int J Clin Pract 2003: 57: 319327.
  • 12
    Rappersberger K, Komar M, Ebelin M E et al. Pimecrolimus: an ascomycin macrolactam derivative for the oral treatment of psoriasis – efficacy, safety, pharmacokinetics and pharmacogenetics. J Invest Dermatol 2002: 119: 876888.DOI: 10.1046/j.1523-1747.2002.00694.x
  • 13
    Griffiths C, Dubertret L, Gottlieb A. Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose-response effect. J Invest Dermatol 2003: 121 (1): 391[Abstract].
  • 14
    Hanifin J, Fleming C, Korman N et al. Treatment with oral pimecrolimus significantly improves atopic dermatitis (AD) with a clear dose-response effect. J Invest Dermatol 2003: 121 (1): 1240[Abstract].
  • 15
    Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999: 141: 264273.DOI: 10.1046/j.1365-2133.1999.02974.x
  • 16
    Winiski A, Wang S, Schwendinger B, Stuetz A. Effect of pimecrolimus, tacrolimus, cyclosporin A, betamethasone 17-valerate, dexamethasone and hydrocortisone on cytokine production and T cell proliferation induced in human peripheral blood mononuclear cells. J Invest Dermatol 2003: 121 (1): 1225[Abstract].
  • 17
    Kalthoff F S, Chung J, Stuetz A. Pimecrolimus inhibits upregulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clin Exp Immunol 2002: 130: 8592.DOI: 10.1046/j.1365-2249.2002.01962.x
  • 18
    Puxeddu I, Piliponsky A M, Bachelet I, Levi-Schaffer F. Mast cells in allergy and beyond. Int J Biochem Cell Biol 2003: 35: 16011607.DOI: 10.1016/S1357-2725(03)00208-5
  • 19
    Hultsch T, Müller K D, Meingassner J G, Grassberger M, Schopf R E, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998: 290: 501507.DOI: 10.1007/s004030050343
  • 20
    Zuberbier T, Chong S U, Grunow K et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001: 108: 275280.DOI: 10.1067/mai.2001.116865
  • 21
    Wollenberg A, Bieber T. Antigen-presenting cells. In: BieberT, LeungD Y, eds. Atopic Dermatitis. Basel: Marcel Dekker AG, 2002: 267283.
  • 22
    Lutz M B, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002: 23: 445449.DOI: 10.1016/S1471-4906(02)02281-0
  • 23
    Kalthoff F S, Chung J, Musser P, Stuetz A. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003: 133: 350359.
  • 24
    Krummen M, A Stuetz T A, Luger S, Grabbe. Effects of pimecrolimus on dendritic cell. J Invest Dermatol 2003: 121 (1): 1224[Abstract].DOI: 10.1046/j.1523-1747.2003.12550_5.x
  • 25
    Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001: 107: 345352.DOI: 10.1067/mai.2001.112600
  • 26
    Tiefenthaler M, Hofer S, Ebner S et al. In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression. Transplantation 2004: 19: 553560.
  • 27
    Schuller E, Oppel T, Bornhovd E, Wetzel S, Wollenberg A. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol 2004: 114: 137143.DOI: 10.1016/j.jaci.2004.03.021
  • 28
    Meingassner J G, Kowalsky E, Schwendinger H, Elbe-Bürger A, Stuetz A. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003: 149: 853857.DOI: 10.1046/j.1365-2133.2003.05559.x
  • 29
    Winiski A, Wang S, Schwendinger B, Stuetz A. Pimecrolimus, tacrolimus, cyclosporine A and corticosteroids: effects on human T cell activation in vitro. J Eur Acad Dermatol Venereol 2003: 17 (Suppl. 3): 353.
  • 30
    Wolff B, Herzig G, Stuetz A. Pimecrolimus does not affect cytokine and chemokine secretion and adhesion molecule expression in primary human keratinocytes and dermal fibroblasts. J Invest Dermatol 2003: 121 (1): 1243[Abstract].
  • 31
    Jackson R. Side effects of potent topical corticosteroids. Can Med Assoc J 1978: 118: 173174.
  • 32
    Takeda K, Arase S, Takahashi S. Side effects of topical corticosteroids and their prevention. Drugs 1988: 36 (Suppl. 5): 1523.
  • 33
    Fisher D A. Adverse effects of topical corticosteroid use. West J Med 1995: 162: 123126.
  • 34
    Abma E M, Blanken R, Heide L J. Cushing's syndrome caused by topical steroid therapy for psoriasis. Neth J Med 2002: 60: 148150.
  • 35
    Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002: 3: 4758.
  • 36
    Billich A, Aschauer H, Aszody A, Stuetz A. Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004: 269: 2935.
  • 37
    Harper J, Lakhanpaul M, Wahn U et al. Pimecrolimus (Elidel®, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic dermatitis (conference abstract). J Eur Acad Dermatol Venereol 2001: 15 (Suppl. 2): 109110.
  • 38
    Allen B R, Lakhanpaul M, Morris A et al. Systemic exposure, tolerability and efficacy of pimecrolimus 1% cream in atopic dermatitis patients. Arch Dis Child 2003: 86: 969973.DOI: 10.1136/adc.88.11.969
  • 39
    Turpeinen M, Salo O P, Leisti S. Effect of percutaneous absorption of hydrocortisone and adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986: 115: 475484.
  • 40
    Draelos Z D, Tofte S, Hanifin J, Chon K. Systemic exposure of pimecrolimus cream 1% and tacrolimus ointment 0.1% in adult patients with moderate to severe atopic dermatitis. Poster presented at AAD, Washington, 6–11 February 2004.
  • 41
    Meingassner J, Stütz A. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 1992: 98: 851855.DOI: 10.1111/1523-1747.ep12456939
  • 42
    Meingassner J, Stütz A. Anti-inflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int Arch Allergy Immunol 1992: 99: 486489.
  • 43
    Meingassner J, Grassberger M, Fahrngruber H, Moore H D, Schuurman H, Stütz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997: 137: 568576.
  • 44
    Meingassner J G, Fahrngruber H. Pimecrolimus (SDZ ASM 981) cream equals tacrolimus (FK506) ointment in efficacy in porcine allergic contact dermatitis. Ann Dermatol Venereol 2002: 129: 1S701.
  • 45
    Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: a randomised, double-blind controlled study. Br J Dermatol 2001: 144: 507513.DOI: 10.1046/j.1365-2133.2001.04076.x
  • 46
    Meingassner J G, Hiestand P, Bigoud M et al. SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506. J Invest Dermatol 2001: 117: 532.
  • 47
    Stuetz A, Grassberger M, Meingassner J G. Pimecrolimus (Elidel®, SDZ ASM 981) – preclinical pharmacological profile and skin selectivity. Semin Cutan Med Surg 2001: 20: 233241.
  • 48
    Meingassner J G, Fahrngruber H, Bavandi A. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporin A. J Invest Dermatol 2003: 121: 7780.DOI: 10.1046/j.1523-1747.2003.12331.x
  • 49
    Neckermann G, Bavandi A, Meingassner J G. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol 2000: 142: 669679.DOI: 10.1046/j.1365-2133.2000.03411.x
  • 50
    Scholzen T E, Steinhoff M, Sindrilaru A et al. Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. FASEB J 2004: 9: 10071009.
  • 51
    Ständer S, Luger T A. Antipruritische Wirkung von Pimecrolimus und Tacrolimus. Hautarzt 2003: 54: 413417.
  • 52
    Steinhoff M, Seeliger S, Ständer S, Grevelhörster A, Stuetz A, Luger T A. Pimecrolimus induces neuropeptide release at early stages of topical application in vivo (conference abstract). IID, April 30 – May 4, 2003. J Invest Dermatol 2003: 121 (1): abstract 1248.
  • 53
    Armstrong C, Jaiani L, Kalden H, Caughman S, Ansel J, Stütz A. The ascomycin derivatives ASM 981 (Pimecrolimus) and ASD 732 inhibit neuroinflammation in cutaneous hypersensitivity. Ann Dermatol Venereol 2002: 129: 1S330.
  • 54
    Hoetzenecker W, Meingassner J G, Ecker R, Stingl G, Stuetz A, Elbe-Buerger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004: 122: 673684.
  • 55
    Roman D, Ulrich P, Paul C et al. Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunization. Toxicol Lett 2004: 149: 133140.DOI: 10.1016/j.toxlet.2003.12.027
  • 56
    Schweitzer A, Figueiredo J, Zehender H, Grassberger M. Pimecrolimus (SDZ ASM 981) has high affinity for the skin – a tissue distribution study in rats in comparison with tacrolimus (FK 506). Ann Dermatol Venereol 2002: 129: 1S704.
  • 57
    Smith D F, Albers M W, Schreiber S L, Leach K L, Deibel M R. FKBP54, a novel FK506-binding protein in avian progesterone receptor complexes and HeLa extracts. J Biol Chem 1993: 268: 2427024273.
  • 58
    Crabtree G R, Olson E N. NFAT signaling: choreographing the social life of cells. Cell 2002: 109: S67S79.
  • 59
    Matsuda S, Moriguchi T, Koyasu S et al. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporine A. J Biol Chem 1998: 273: 1237812382.DOI: 10.1074/jbc.273.20.12378
  • 60
    Matsuda S, Shibasaki F, Takehana K et al. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep 2000: 1: 428434.DOI: 10.1093/embo-reports/kvd090
  • 61
    Kehren J, Hartmann B, Fahrngruber H, Stuetz A, Meingassner J G. Pimecrolimus and tacrolimus differentially affect genes related to skin inflammation in rats. J Invest Dermatol 2003: 121 (1): 1192[Abstract].
  • 62
    Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002: 110: e2.DOI: 10.1542/peds.110.1.e2
  • 63
    Ho V, Gupta A, Kaufmann R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003: 142: 155162.DOI: 10.1067/mpd.2003.65
  • 64
    FDA/Center for Drug Evaluation and Research. Elidel (pimecrolimus) cream. [Retrieved from].
  • 65
    Tran C, Lübbe J, Antille C et al. Calcineurin inhibitors and skin cancer. J Invest Dermatol 2003: 121: 1072A.
  • 66
    Kalthoff F S, Chung J, Musser P, Wang S, Stuetz A. Pimecrolimus and tacrolimus show comparable potencies to inhibit the proliferation and cytokine synthesis of allergen-specific, atopic skin-derived T cell clones in vitro. J Invest Dermatol 2004: 122: A119.
  • 67
    Billich A, Aschauer H, Stuetz A. In vitro penetration/permeation of pimecrolimus and tacrolimus from their marketed formulations (Elidel and Protopic). J Invest Dermatol 2004: 122: A40.
  • 68
    Meingassner J G, Fahrngruber H, Schweitzer A, Figureido J, Zehender H, Stütz A. Pimecrolimus (SDZ ASM 981) and tacrolimus (FK 506) target skin and peripheral lymphoid organs differently in mice and rats. Ann Dermatol Venereol 2002: 129: 1S701.